Beyond TNBC, further studies on the role of vitamin C in PI3K inhibitors in treating HR+ breast cancer in combination with endocrine therapy, and in treating HER2+ breast cancer in combination with anti-HER2 therapy are warranted. The gene discussed is PIK3CA; the disease is breast carcinoma.